Janus

Janus International Group to Report Fourth Quarter and Full Year 2023 Results on February 28, 2024

Retrieved on: 
Wednesday, February 14, 2024
Other Manufacturing, Commercial Building & Real Estate, Technology, Construction & Property, Other Technology, Professional Services, Manufacturing, Other Construction & Property, Other Professional Services, Janus, Domestic, International, JBI, International Marxist Group, Conference, Webcast, Video game

A webcast and conference call will be held that same day at 10:00 a.m.

Key Points: 
  • A webcast and conference call will be held that same day at 10:00 a.m.
  • ET to review the Company’s fourth quarter and full year results and conduct a question-and-answer session.
  • Upon dialing in, please request to join the Janus International Group Fourth Quarter 2023 Earnings Conference Call.
  • To access the replay of the call, dial 1-844-512-2921 (Domestic) or 1-412-317-6671 (International) with pass code 13743925.

Janus Henderson to Present at Bank of America Securities 2024 Financial Services Conference

Retrieved on: 
Tuesday, February 13, 2024
Consulting, Asset Management, Professional Services, Finance, Janus, Bank, Webcast, Janus Henderson, Conference

Janus Henderson Group plc (NYSE: JHG; “JHG” or the “Company”) announced today that Ali Dibadj, CEO, is scheduled to speak at the Bank of America Securities 2024 Financial Services Conference in Miami on February 20, 2024, beginning at approximately 3:00 p.m.

Key Points: 
  • Janus Henderson Group plc (NYSE: JHG; “JHG” or the “Company”) announced today that Ali Dibadj, CEO, is scheduled to speak at the Bank of America Securities 2024 Financial Services Conference in Miami on February 20, 2024, beginning at approximately 3:00 p.m.
  • ET.
  • A live webcast will be available via the investor relations section of the Janus Henderson website ( ir.janushenderson.com ).
  • A replay of the webcast will be available within 24 hours of the presentation and will remain accessible through the Company’s website for three months.

PPM America Adds PGIM Principal To Global Distribution Team

Retrieved on: 
Monday, February 12, 2024
Finance, Banking, Professional Services, Asset Management, Human Resources, Janus, Senior, Private equity, Loomis, Sayles & Company, Multimedia, PPM, Bond credit rating, PGIM, Axa Investment Managers, Janus Henderson, Management

PPM America, Inc. (PPM) today announced the hiring of Jamison Gagnier to its Global Distribution team as a Senior Managing Director.

Key Points: 
  • PPM America, Inc. (PPM) today announced the hiring of Jamison Gagnier to its Global Distribution team as a Senior Managing Director.
  • Gagnier is a seasoned industry professional with over 25 years of experience, most recently serving as a Principal on PGIM’s Institutional Client Advisor team.
  • View the full release here: https://www.businesswire.com/news/home/20240212700886/en/
    PPM America adds Jamison Gagnier to its Global Distribution team as Senior Managing Director.
  • “PPM has quietly gone about its business for over 30 years, and now we are well-positioned to build upon that foundation.”

PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

Retrieved on: 
Wednesday, February 7, 2024
Janus, Security (finance), SVB Securities, Research, Form S-3, Telephone, Prospectus, Sale, State Street, Form, Pharmaceutical industry

The aggregate gross proceeds to PepGen from this offering are expected to be approximately $80.1 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen.

Key Points: 
  • The aggregate gross proceeds to PepGen from this offering are expected to be approximately $80.1 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen.
  • The offering is expected to close on or about February 9, 2024, subject to customary closing conditions.
  • Leerink Partners is acting as the sole book-running manager for the offering.
  • PepGen currently intends to use the net proceeds from this offering to fund ongoing research and clinical development of its product candidates, as well as for working capital and other general corporate purposes.

Dianthus Therapeutics Announces $230 Million Private Placement

Retrieved on: 
Monday, January 22, 2024
Janus, Jefferies, PIPE, Therapy, Research, Guggenheim Partners, Investment, Evercore, Public expenditure, Sale, Dianthus, Security (finance)

NEW YORK and WALTHAM, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus” or the “Company”) (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $230 million to the Company, before deducting placement agent fees and offering expenses.

Key Points: 
  • NEW YORK and WALTHAM, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus” or the “Company”) (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $230 million to the Company, before deducting placement agent fees and offering expenses.
  • The PIPE financing is expected to close on or about January 24, 2024, subject to satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the PIPE financing, together with the Company’s existing cash, cash equivalents, and marketable securities, for research and development expenditures focused on product development and for general corporate purposes, including capital expenditures, working capital and potential business development activities.
  • Jefferies, Evercore ISI, Stifel, Guggenheim Securities, and Raymond James are acting as placement agents for the PIPE financing.

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

Retrieved on: 
Friday, January 19, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Janus, Citadel, Myopathy, Patient, Therapy, Research, SVB Securities, OrbiMed, Edgewise, Prospectus, Novo Holdings A/S, Form, Sale, Becker muscular dystrophy, ATTN:, Montgomery Street, Attention, Telephone, State Street

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.

Key Points: 
  • Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.
  • Edgewise anticipates gross proceeds from the offering to be approximately $240 million, before deducting underwriting discounts and commissions and offering expenses.
  • The closing of the offering is expected to occur on January 23, 2024, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC.

Janus International Group and Trojan Storage to Expand Implementation of the Nokē™ Smart Entry System

Retrieved on: 
Tuesday, January 16, 2024
Commercial Building & Real Estate, Technology, Manufacturing, Construction & Property, IOT (Internet of Things), Professional Services, Other Technology, Other Manufacturing, Data Analytics, Mobile, Wireless, Other Construction & Property, Janus, Partnership, International Marxist Group, JBI, Warehouse

Janus and Trojan have partnered to bring Nokē smart technology to 5,000 units across nine of Trojan’s facilities to date.

Key Points: 
  • Janus and Trojan have partnered to bring Nokē smart technology to 5,000 units across nine of Trojan’s facilities to date.
  • “We’ve been incredibly pleased with the rollout of the Nokē system across nine of our facilities.
  • Integrating Nokē ONE smart locks and Nokē’s technology at our entry points has enabled us to further our commitment to providing a first-class storage experience for our customers,” said Brett Henry, President of Trojan Storage.
  • The Nokē Smart Entry System by Janus combines its best-in-class self-storage offerings with new and innovative technologies to redefine the total self-storage experience.

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

Retrieved on: 
Tuesday, January 9, 2024
Well, Janus, STAT3, Patient, Janus kinase, Lymphoma, Therapy, Lupus, ALL, TPD, Asthma, Hematology, STAT6, JAK, Roflumilast, Inflammatory bowel disease, Society, HS, Cancer, Bone marrow, Arm, Q&A, Acute leukemia, IND, MDM2, Autoimmunity, Conference, Interim, Inflammation, TYK2, Psoriasis, Toxicity, Webcast, Clinical trial, File, Atopic dermatitis, Blood, Pharmaceutical industry

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.
  • Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
  • KT-621 has potentially broad utility across a number of allergic diseases, including atopic dermatitis, asthma and chronic obstructive pulmonary disorder, among others.
  • Kymera is working to develop a biomarker-based patient selection strategy for subsequent development beyond Phase 1a.

Solid Biosciences Announces $109 Million Private Placement

Retrieved on: 
Monday, January 8, 2024
Janus, Cantor, Sale, LP, Citigroup, Prospectus, Exercise, Security (finance)

The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).

Key Points: 
  • The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).
  • Citigroup and Cantor acted as joint lead placement agents to the Company in connection with the private placement.
  • The Company expects to use net proceeds from the private placement to fund ongoing pipeline development programs, business development activities, and for working capital and other general corporate purposes.
  • The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement no later than the 30th day after the closing of the private placement.

Janus Henderson to Report Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Friday, January 5, 2024
Professional Services, Finance, Consulting, Asset Management, Banking, Accounting, Janus, Conference

Janus Henderson Group plc (NYSE: JHG) will announce its fourth quarter and full-year 2023 results on Thursday, February 1, 2024, at 7:30 a.m.

Key Points: 
  • Janus Henderson Group plc (NYSE: JHG) will announce its fourth quarter and full-year 2023 results on Thursday, February 1, 2024, at 7:30 a.m.
  • ET.
  • A conference call and webcast to discuss the results will be held at 9:00 a.m.
  • Those wishing to participate in the conference call should call the applicable number below and reference the Janus Henderson Results Briefing (Conference ID: 235741):